BIOLOGICS MARKET ANALYSIS

Biologics Market, By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, and Others), By Drug Classification (Branded Drugs and Generic Drugs), By Route of Administration (Oral, Parenteral, and Other Routes), By Mode of Purchase (Prescription-Based Drugs and Over-The-Counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa).

On December 1, 2024, Biocon Biologics Ltd., a global biopharmaceutical company specializing in biosimilars, announced that the U.S. Food and Drug Administration (FDA) had approved YESINTEK (ustekinumab-kfce), a biosimilar to Janssen's Stelara (ustekinumab). YESINTEK is indicated for the treatment of several autoimmune conditions, including Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. This approval marks a significant advancement in providing more accessible treatment options for patients with chronic autoimmune diseases.
In July 2024, Lonza Group, a Swiss multinational chemicals and biotechnology company, reported a smaller-than-expected decline in first-half profits, attributed to strong performance in its Biologics unit, despite challenges in other segments
In May 2024, Biogen Inc., a leading biotechnology company specializing in neurological treatments, announced the acquisition of Human Immunology Biosciences for US$ 1.15 billion upfront, with up to US$ 650 million in potential milestone payments. This move aims to strengthen Biogen's immunology portfolio.
In May 2024, Genmab, a biotechnology company specializing in antibody therapeutics for cancer, acquired ProfoundBio, a U.S.-Chinese drugmaker, for US$ 1.8 billion. This acquisition aims to bolster Genmab's position in the biologics market.